Gene Vector Market - By Vector (Plasmid DNA, Adeno-Associated Viral, Retroviral), By Application (Gene Therapy, Vaccinology), By Disease (Oncology, Genetic, Infectious) By End-user (CDMO, CRO, Pharma & Biotech Companies), Global Forecast 2023-2032

Gene Vector Market - By Vector (Plasmid DNA, Adeno-Associated Viral, Retroviral), By Application (Gene Therapy, Vaccinology), By Disease (Oncology, Genetic, Infectious) By End-user (CDMO, CRO, Pharma & Biotech Companies), Global Forecast 2023-2032

Global Gene Vector Market size will expand considerably through 2032. Growing number of clinical trials will pave the way for industry growth. Many clinical trials explore the potential of combination therapies, where gene therapy is combined with other treatment modalities such as chemotherapy, radiation therapy, or immunotherapy. These combination approaches often involve the use of multiple gene vectors to deliver different therapeutic agents or enhance treatment synergies. The increasing exploration of combination therapies in clinical trials contributes to the higher demand for gene vectors.

The overall gene vector market is classified based on vector, application, diseases, end-user, and region.

Based on the vector, industry share from the lentiviral segment will grow at a substantial CAGR from 2023 to 2032. Increasing investment in gene therapy will generate lucrative opportunities for segment growth. Lentiviral vectors are widely used as vehicles for delivering genes into target cells. They can efficiently transfer genetic material, such as therapeutic genes, to a range of cell types, including non-dividing or slowly dividing cells. This ability makes them valuable in gene therapy, where they are used to treat genetic disorders.

Based on diseases, industry share from the infectious disease segment will grow at a significant CAGR from 2023 to 2032. Growing prevalence of infectious diseases has increased the demand for gene vectors. Gene vectors can be used to develop vaccines against infectious diseases. They can deliver specific antigen genes into host cells, triggering an immune response and the production of protective antibodies. This approach offers advantages such as the ability to generate a broad immune response, including cellular immunity, and the potential to rapidly develop vaccines for emerging infectious diseases.

Based on the end-user, industry value from the CROs segment will register significant gains through 2032. Increasing number of CROs is contributing to segment growth. Moreover, rising efforts by these organizations toward the development of gene therapies are further creating a notable impetus for segment expansion. CROs conduct preclinical studies using gene vectors to assess the safety and efficacy of potential gene therapies or gene-based treatments.

Regionally, the Asia Pacific gene vector market share will grow at an exponential CAGR from 2023 to 2032. Growing occurrence of infectious disorders such as HIV/AIDS has increased the demand for gene vectors in the region. Moreover, rapidly expanding healthcare infrastructure is further contributing to regional growth. As per IBEF, in the Union Budget 2023-24, the government of India awarded USD 10.76 billion to the Ministry of Health and Family Welfare.